Legato Capital Management LLC purchased a new stake in shares of Astrana Health, Inc. (NASDAQ:ASTH – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 27,739 shares of the company’s stock, valued at approximately $688,000.
A number of other large investors also recently modified their holdings of ASTH. Ameriprise Financial Inc. increased its holdings in shares of Astrana Health by 231.0% during the third quarter. Ameriprise Financial Inc. now owns 442,314 shares of the company’s stock valued at $12,540,000 after purchasing an additional 308,665 shares during the period. 325 Capital LLC increased its holdings in shares of Astrana Health by 34.6% during the third quarter. 325 Capital LLC now owns 1,193,953 shares of the company’s stock valued at $33,849,000 after purchasing an additional 307,037 shares during the period. Insight Wealth Strategies LLC acquired a new position in shares of Astrana Health during the fourth quarter valued at $3,514,000. Hotchkis & Wiley Capital Management LLC increased its holdings in shares of Astrana Health by 44.2% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 421,710 shares of the company’s stock valued at $11,955,000 after purchasing an additional 129,270 shares during the period. Finally, AXA S.A. acquired a new position in shares of Astrana Health during the second quarter valued at $3,150,000. 52.77% of the stock is owned by institutional investors and hedge funds.
Astrana Health Price Performance
NASDAQ:ASTH opened at $38.54 on Wednesday. The business’s 50-day moving average price is $31.28 and its 200 day moving average price is $26.19. The firm has a market cap of $2.15 billion, a P/E ratio of 63.18 and a beta of 0.98. Astrana Health, Inc. has a 52-week low of $18.08 and a 52-week high of $39.93. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.20.
Analyst Upgrades and Downgrades
ASTH has been the topic of a number of research analyst reports. Barclays raised Astrana Health from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $37.00 to $50.00 in a report on Tuesday. Robert W. Baird set a $45.00 target price on Astrana Health in a report on Friday, May 8th. Zacks Research raised Astrana Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, March 11th. BTIG Research lifted their target price on Astrana Health from $40.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, May 8th. Finally, Weiss Ratings raised Astrana Health from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Astrana Health presently has a consensus rating of “Moderate Buy” and an average price target of $45.00.
Get Our Latest Stock Analysis on Astrana Health
About Astrana Health
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
See Also
- Five stocks we like better than Astrana Health
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding ASTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrana Health, Inc. (NASDAQ:ASTH – Free Report).
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
